EMA Application withdrawn: Duloxetine Sandoz (duloxetine) — Sandoz GmbH

View source ↗

Summary

EMA withdrawn application for Duloxetine Sandoz (duloxetine) by Sandoz GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Diabetes Mellitus
• Major Depressive Disorder
• Neuralgia

Drugs mentioned

• Duloxetine Sandoz (duloxetine)

Snippet

Status: Application withdrawn. Therapeutic area: Anxiety Disorders;Neuralgia;Diabetes Mellitus;Depressive Disorder, Major. MAH: Sandoz GmbH. Decision date: 24/04/2015